Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco.23.02262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Claire Gallois und 20 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, France. Hauptthemen laut MEDLINE: Tumor Microenvironment, Colonic Neoplasms, Transcriptome, Cell Cycle. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE The objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis of transcriptomic signatures of the tumor microenvironment (TME) and cell cycle from the PETACC-8 (training set) and IDEA-France (validation set) trials. PATIENTS AND METHODS 3'RNA sequencing was performed in 1,733 patients from the PETACC-8 trial and 1,248 patients from the IDEA-France trial. Four transcriptomic signatures were analyzed: T-cell and macrophage M2 signatures, the expression of CXCL13, and a score on the basis of the Oncotype DX CC Recurrence Score using the same formula from the stromal score and the cell cycle score. The Immune Proliferative Stromal (IPS) score was defined as the number of dichotomized signatures that fall under the category of a dismal prognosis (from 0 to 4). Time to recurrence (TTR) was defined as the time from the date of random assignment to local and/or metastatic relapse and/or death because of CC, whichever occurs first. RESULTS High Oncotype-like and M2 scores and low CXCL13 expression and T-cell score were associated with a shorter TTR. A multivariable model including these signatures and all known prognostic factors applied to the IDEA-France cohort by obtaining a value of this model for each patient showed TTR significantly different depending on the quartile of this value and a 3-year rate of patients without recurrence ranging from 56% for the lowest quartile to 89% for the highest quartile ( P < .0001). The IPS score was significantly associated with TTR in multivariable analysis. CONCLUSION Using transcriptomic data of patients with stage III CC from two large-scale adjuvant trials, a prognostic model on the basis of signatures of the TME and the cell cycle provides important information in addition to known prognostic factors for patient stratification on risk of recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, Paris, France.
- Digestive Oncology Department, Institut du Cancer Paris CARPEM, APHP, APHP Centre, Hôpital Européen G. Pompidou, Université Paris Cité, Paris, France.
- Institut Chimie Biologie Innovation-Laboratoire de BioChimie, ESPCI, UMR8231 CNRS, Université PSL, Paris, France.
- Department of Medical Oncology, Hôpital Saint Antoine, Sorbonne Université, Paris, France.
- Methodology and Quality of Life Unit in Oncology, University of Besançon, Besançon, France.
- Etablissement Français du Sang Bourgogne Franche-Comté, INSERM, Unité Mixte de Recherche 1098, RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Franche-Comté University, Besançon University Hospi…
ORCID-Profile: Claire Gallois, Marine Sroussi, Thierry André, Sophie Mouillet-Richard, Jean-Baptiste Bachet, Marine Jary, Josep Tabernero, Côme Lepage, Jean-François Emile, Julien Taieb, Pierre Laurent-Puig
Zitieren
APA
Gallois, C., Sroussi, M., André, T., Mouillet-Richard, S., Agueeff, N., Mulot, C., Vernerey, D., Louvet, C., Bachet, J. B., Dourthe, L. M., Mazard, T., Jary, M., Coutzac, C., Lecaille, C., Tabernero, J., Van Laethem, J. L., Lepage, C., Emile, J. F., de Reyniès, A., …, & Laurent-Puig, P. (2025). Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02262
Vancouver
Gallois C, Sroussi M, André T, Mouillet-Richard S, Agueeff N, Mulot C, et al. Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials. Journal of Clinical Oncology. 2025. doi:10.1200/jco.23.02262
BibTeX
@article{Gallois2025,
author = {Gallois, Claire and Sroussi, Marine and André, Thierry and Mouillet-Richard, Sophie and Agueeff, Natacha and Mulot, Claire and Vernerey, Dewi and Louvet, Christophe and Bachet, Jean-Baptiste and Dourthe, Louis-Marie and Mazard, Thibault and Jary, Marine and Coutzac, Clélia and Lecaille, Cédric and Tabernero, Josep and Van Laethem, Jean-Luc and Lepage, Côme and Emile, Jean-François and de Reyniès, Aurélien and Taieb, Julien and Laurent-Puig, Pierre},
title = {Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco.23.02262}
}
EUVIMED